ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : Ä¡·áº°, Á¦Ç°º°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2033³â)
Thoracic Aortic Aneurysm Market Size, Share & Trends Analysis Report By Treatment (Open Surgical Repair (OSR), Thoracic Endovascular Aneurysm Repair (TEVAR)), By Product, By End Use, By Region, And Segment Forecasts, 2025 - 2033
»óǰÄÚµå : 1813855
¸®¼­Ä¡»ç : Grand View Research
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,413,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,827,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,655,000
Printable PDF & Excel (Enterprise License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(ÀÚȸ»ç Æ÷ÇÔ)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â ÆÄÀÏÀÇ ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå ¿ä¾à

ÈäºÎ ´ëµ¿¸Æ·ù ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 16¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2033³â¿¡´Â 50¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2033³â ¿¬Æò±Õ 13.36% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÌ·¯ÇÑ ¼ºÀåÀÇ ¿øµ¿·ÂÀº °íÇ÷¾Ð ¹× °áÇÕÁ¶Á÷ ÁúȯÀÇ À¯º´·ü Áõ°¡, °í·ÉÈ­ Àα¸ Áõ°¡, Àúħ½ÀÀû Ç÷°ü³» Ä¡·áÀÇ Ã¤Åà Ȯ´ë¿¡ ±âÀÎÇÕ´Ï´Ù.

½ºÅÙÆ® ±×¶óÇÁÆ® ¼³°èÀÇ ±â¼úÀû Áøº¸, ¿µ»ó Áø´ÜÀÇ °³¼±, Áúº´ÀÇ Á¶±â ¹ß°ß µîÀÌ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. º¸Çè ±Þ¿© Á¤Ã¥ ¹× ÀÇ»ç¿Í ȯÀÚ ¸ðµÎ¿¡ ´ëÇÑ ÈäºÎ ´ëµ¿¸Æ·ù¿¡ ´ëÇÑ ÀνÄÀÌ È®´ëµÊ¿¡ µû¶ó Àü ¼¼°èÀûÀ¸·Î Ä¡·á µµÀÔÀÌ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

ÈäºÎ ´ëµ¿¸Æ·ùÀÇ ÁÖ¿ä À§Çè ¿äÀÎÀÎ °íÇ÷¾Ð, Èí¿¬, µ¿¸Æ°æÈ­ÁõÀÇ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î °í·ÉÈ­°¡ ÁøÇàµÊ¿¡ µû¶ó ÅðÇ༺ Ç÷°ü ÁúȯÀÇ ¹ß»ý·üÀº °è¼Ó Áõ°¡Çϰí ÀÖÀ¸¸ç, Áø´Ü ¹× Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Á÷Á¢ÀûÀ¸·Î Áõ°¡Çϰí ÀÖ½À´Ï´Ù. 2025³â 3¿ù Biomedicines Àú³Î¿¡ °ÔÀçµÈ ³í¹®¿¡¼­´Â Á׻󵿸ưæÈ­Áõ(AS)°ú ÈäºÎµ¿¸Æ·ù(TAA)¸¦ Æ÷ÇÔÇÑ ´ëµ¿¸Æ·ù(AA)ÀÇ °ü°è¸¦ ºÐ¼®ÇÏ¿´½À´Ï´Ù. µ¿¸Æ·ùÀÇ À§Ä¡, ³ªÀÌ, À¯ÀüÀû ¹è°æ, ÀÌ÷´ëµ¿¸ÆÆÇ¸· µîÀÇ ¿µÇâÀ» ¹Þ¾Æ µ¿¹ÝÀ²Àº 18%¿¡¼­ 90%¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

Ç÷°ü ³» µ¿¸Æ·ù Ä¡·á¼ú(TEVAR)ÀÇ ±â¼ú ¹ßÀüÀº °³º¹ ¼ö¼úÀÇ ´ë¾ÈÀ¸·Î ÃÖ¼Ò Ä§½ÀÀû ¼ö¼úÀ» Á¦°øÇÔÀ¸·Î½á ½ÃÀåÀ» Å©°Ô ¼ºÀå½ÃÄ×½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ÀÔ¿ø ±â°£ ´ÜÃà, ¼ö¼ú À§Çè °¨¼Ò, °íÀ§Ç豺 ȯÀÚ Ä¡·á ´ë»ó È®´ë µîÀ¸·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ÀÇ·á±â±â Á¦Á¶¾÷üµéÀº Á¤È®¼º, À¯¿¬¼º, ³»±¸¼ºÀ» Çâ»ó½ÃŲ Â÷¼¼´ë ½ºÅÙÆ® ±×¶óÇÁÆ®¸¦ Áö¼ÓÀûÀ¸·Î °³¹ßÇϰí ÀÖÀ¸¸ç, Àü ¼¼°è Ç÷°ü¿Ü°ú ÀÇ»çµéÀÇ Ã¤ÅÃÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. 2025³â 5¿ù, ´ÙÄ«¿¡ À§Ä¡ÇÑ SHIP ±¹Á¦º´¿øÀº ÈäºÎ ´ëµ¿¸Æ·ù(TAA)¸¦ ¾Î°í ÀÖ´Â 57¼¼ ȯÀÚ¿¡°Ô ÈäºÎ Ç÷°ü ³» ´ëµ¿¸Æ º¹¿ø¼ú(TEVAR)À» ½ÃÇàÇß½À´Ï´Ù. ´Ù¸¥ °÷¿¡¼­ Ä¡·á¸¦ °ÅºÎ´çÇÑ ÈÄ NICVD ±³¼ö·ÎºÎÅÍ ¼Ò°³¹ÞÀº ÀÌ È¯ÀÚ´Â Ç÷°ü ³» ½ºÅÙÆ® ÀÌ½Ä º¥´õÀÇ Áö¿øÀ» ¹Þ¾Æ ÃÖ¼Ò Ä§½À ¼ö¼úÀ» ¹Þ¾Ò½À´Ï´Ù.

ÈäºÎ ´ëµ¿¸Æ·ù¸¦ Á¶±â¿¡ Á¤È®ÇÏ°Ô ¹ß°ßÇϱâ À§ÇØ CT, MRI, ÃÊÀ½ÆÄ µî ÷´Ü ¿µ»óÁø´Ü ±â¹ýÀÇ »ç¿ëÀÌ Áõ°¡Çϸ鼭 ½ÃÀå ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. Àü±¹ÀûÀÎ °ËÁø ÇÁ·Î±×·¥°ú ÀÓ»óÀÇ¿Í È¯ÀÚ ¸ðµÎÀÇ ÀÎ½Ä °³¼±Àº Á¶±â Áø´Ü°ú Àû½Ã °³ÀÔ¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² ÀΰøÁö´É µµ±¸¿Í µðÁöÅÐ Çコ Ç÷§ÆûÀÌ Áø´Ü °æ·Î¿¡ ÅëÇÕµÇ¾î ´õ ³ªÀº À§Çè °èÃþÈ­ ¹× ȯÀÚ ¸ð´ÏÅ͸µÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù.

2025³â 6¿ù Nature Communications¿¡ °ÔÀçµÈ ³í¹®Àº ÀÏ»óÀûÀÎ À¯¹æ MRI ½ºÄµÀ» ÅëÇØ ÈäºÎ ´ëµ¿¸Æ·ù(TAA)ÀÇ ±âȸÁÖÀÇÀûÀÎ ½ºÅ©¸®´×À» °¡´ÉÇÏ°Ô ÇÏ´Â AI ¸ðµ¨¿¡ ´ëÇØ ³íÀÇÇß½À´Ï´Ù. ÀÌ ¸ðµ¨Àº Ç¥ÁØ ÀÓ»ó °Ë»ç¿¡ ºñÇØ °ËÃâ·üÀ» 3.5¹è Çâ»ó½ÃÄ×½À´Ï´Ù. ÀÌ ¸ðµ¨Àº ´ëµ¿¸ÆÀÇ Å©±â¿Í AHI, ASI¿Í °°Àº ü°Ý Á¶Á¤ ÁöÇ¥¸¦ ±â¹ÝÀ¸·Î °íÀ§Ç豺 ȯÀÚ¿¡°Ô Ç÷¡±×¸¦ Ç¥½ÃÇß½À´Ï´Ù.

¼¼°è ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå ¼¼ºÐÈ­

¼¼°èÀÇ ÈäºÎ ´ëµ¿¸Æ·ù(ÈäºÎ ´ëµ¿¸Æ·ù) ½ÃÀåÀ» ºÐ¼®ÇÏ¿© 2021³â-2033³â±îÁö °¢ ÇÏÀ§ ºÎ¹®ÀÇ ¼öÀÍ ¼ºÀåÀ» ¿¹ÃøÇϰí, ¼¼°è, Áö¿ª ¹× ±¹°¡º° Ãֽе¿Ç⠺м®À» Á¦°øÇÕ´Ï´Ù. ÀÌ º¸°í¼­´Â ¼¼°è ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀåÀ» Ä¡·á, Á¦Ç°, ÃÖÁ¾ ¿ëµµ ¹× Áö¿ªº°·Î ºÐ·ùÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¼¼°èÀÇ ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ¼¼°èÀÇ ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå ºÎ¹® ºÐ¼®, Ä¡·á, 2021³â-2033³â

Á¦5Àå ¼¼°èÀÇ ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå ºÎ¹® ºÐ¼®, Á¦Ç°º°, 2021-2033³â

Á¦6Àå ¼¼°èÀÇ ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå ºÎ¹® ºÐ¼®, ÃÖÁ¾ ¿ëµµº°, 2021³â-2033³â

Á¦7Àå ÈäºÎ ´ëµ¿¸Æ·ù ½ÃÀå ºÎ¹® ºÐ¼®, Áö¿ªº°, 2021³â-2033³â

Á¦8Àå °æÀï ±¸µµ

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Thoracic Aortic Aneurysm Market Summary

The global thoracic aortic aneurysm market size was estimated at USD 1.65 billion in 2024 and is projected to reach USD 5.04 billion by 2033, growing at a CAGR of 13.36% from 2025 to 2033. This growth is driven by the rising prevalence of hypertension and connective tissue disorders, an increasing aging population, and growing adoption of minimally invasive endovascular procedures.

Technological advancements in stent graft design, improved diagnostic imaging, and early disease detection contribute to market expansion. Supportive reimbursement policies and expanding awareness of thoracic aortic aneurysms among both physicians and patients are further accelerating treatment uptake globally.

The increasing prevalence of hypertension, smoking, and atherosclerosis, which are key risk factors for thoracic aortic aneurysm, is a major driver of market growth. As aging populations grow globally, the incidence of degenerative vascular conditions continues to rise, directly increasing the demand for diagnostic and therapeutic solutions. In March 2025, an article published in Biomedicines analyzed the relationship between atherosclerosis (AS) and aortic aneurysm (AA), including thoracic AA (TAA). It reported comorbidity rates ranging from 18% to 90%, influenced by aneurysm location, age, genetic background, and bicuspid aortic valves.

Technological advancements in endovascular aneurysm repair (TEVAR) have significantly boosted the market by offering minimally invasive alternatives to open surgery. These innovations have led to reduced hospital stays, lower procedural risks, and expanded treatment eligibility for high-risk patients. Device manufacturers are continually developing next-generation stent grafts with enhanced precision, flexibility, and durability, further accelerating their adoption among vascular surgeons worldwide. In May 2025, SHIP International Hospital in Dhaka performed a Thoracic Endovascular Aortic Repair (TEVAR) on a 57-year-old patient with a thoracic aortic aneurysm (TAA), a bulge in the chest portion of the aorta. Referred by a NICVD professor after being denied treatment elsewhere, the patient underwent the minimally invasive procedure with support from an endovascular stent graft vendor.

The growing use of advanced imaging modalities such as CT angiography, MRI, and ultrasound for early and accurate detection of thoracic aortic aneurysms is fueling market growth. National screening programs and increased awareness among both clinicians and patients are contributing to earlier diagnosis and timely intervention. In parallel, artificial intelligence tools and digital health platforms are being integrated into diagnostic pathways, supporting better risk stratification and patient monitoring.

In June 2025, an article published in Nature Communications discussed an AI model that enables opportunistic screening for thoracic aortic aneurysms (TAA) using routine breast MRI scans. The model improved detection rates by 3.5X compared to standard clinical reads. It flagged high-risk patients based on both aortic size and body-size-adjusted indices like AHI and ASI.

Global Thoracic Aortic Aneurysm Market Segmentation

This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global thoracic aortic aneurysm market report based on treatment, product, end use, and region:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Global Thoracic Aortic Aneurysm Market Variables, Trends & Scope

Chapter 4. Global Thoracic Aortic Aneurysm Market Segment Analysis, By Treatment, 2021-2033 (USD Million)

Chapter 5. Global Thoracic Aortic Aneurysm Market Segment Analysis, By Product, 2021-2033 (USD Million)

Chapter 6. Global Thoracic Aortic Aneurysm Market Segment Analysis, By End Use, 2021-2033 (USD Million)

Chapter 7. Thoracic Aortic Aneurysm Market Segment Analysis, By Region, 2021- 2033 (USD Million)

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â